Provided by Tiger Trade Technology Pte. Ltd.

HCW Biologics Inc.

1.22
+0.8830262.02%
Post-market: 1.03-0.1897-15.55%19:59 EDT
Volume:394.92M
Turnover:438.27M
Market Cap:8.22M
PE:-0.11
High:1.42
Open:1.11
Low:0.9910
Close:0.3370
52wk High:10.00
52wk Low:0.2500
Shares:6.73M
Float Shares:2.88M
Volume Ratio:54.69
T/O Rate:13697.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.6300
EPS(LYR):-30.9580
ROE:-27725.96%
ROA:-31.19%
PB:2.97
PE(LYR):-0.04

Loading ...

Why Is Penny Stock HCW Biologics (HCWB) Up Today?

TIPRANKS
·
Yesterday

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM

Reuters
·
May 15

Top Premarket Gainers

MT Newswires Live
·
May 15

Dawson Geophysical (DWSN) Stock Surges Over 16% Overnight: Why Is It Moving?

Benzinga
·
May 15

HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session

Benzinga
·
May 15

HCW Biologics swings to Q1 profit of $3.47 million; revenue rises to $6.54 million

Reuters
·
May 15

HCW Biologics Q1 revenue surges on licensing deal

Reuters
·
May 15

HCW Biologics Q1 EPS $0.37 Beats $(0.44) Estimate, Sales $6.543M Up From $5.065K YoY

Benzinga
·
May 15

HCW Biologics: on Track to Report Phase 1 HCW9302 Alopecia Data in H1 2026

THOMSON REUTERS
·
May 15

HCW Biologics, Inc Q1 Basic EPS USD 0.37

THOMSON REUTERS
·
May 15

Press Release: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

Dow Jones
·
May 15

HCW Biologics discovers HCW11-040 prevents bronchopulmonary dysplasia

TIPRANKS
·
May 14

BRIEF-HCW Biologics Discovers That HCW11-040 Prevents Bronchopulmonary Dysplasia During IND-Enabling Studies

Reuters
·
May 14

HCW Biologics Inc - Expects to Complete Ind-Enabling Studies in H2 2027 and File Ind Application for HCW11-040

THOMSON REUTERS
·
May 14

HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies

GlobeNewswire
·
May 14

HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

GlobeNewswire
·
May 01

HCW Biologics Inc - Agreement to Commence on or About May 1, 2026, Subject to Public Offering Close - SEC Filing

THOMSON REUTERS
·
Apr 30

HCW Biologics Inc - on April 25, Co to Enter $2.5 Mln Marketing Consulting Agreement With I.r. Agency Llc - SEC Filing

THOMSON REUTERS
·
Apr 30

HCW Biologics to file IND for HCW11-018b in first half of 2027

TIPRANKS
·
Apr 27

BRIEF-Hcw Biologics Delivers A Major Update For Its T-Cell Engager Program Revealing Mechanism Of Action

Reuters
·
Apr 27